DGAP-News: va-Q-tec AG / Key word(s): Miscellaneous
va-Q-tec: Service business for pharmaceutical and biotech industry records significant progress and grows by 54% in H1 2017
- Growth in service business in H1 2017 of 54% to EUR 8.8 million
- Major new customers acquired in the container rental business and business with existing customers grows; H1 2017 revenue at EUR 6.9 million (+41% compared with H1 2016)
- Container rental network expanded to 300 commercial routes as of the end of H1 2017 (+125 routes year-on-year)
- Container fleet grows by more than 200 containers in H1 2017; approximately 250 further planned for second half of the year
- More than 1,200 rental containers, largest passively temperature controlled fleet worldwide; new network stations in Japan, India, Australia and Italy, 25 active network stations
- Airline partnerships agreed with Emirates SkyCargo, TAP Cargo and Egyptair Cargo
- Box rental business up by more than 100% from EUR 0.8 million to EUR 1.7 million in H1 2017
Würzburg, 18. September 2017. va-Q-tec AG (ISIN DE0006636681 / WKN 663668), a technologically leading provider of highly efficient products and solutions in the area of thermal insulation and cold chain logistics, reports significant progress in the development of the service business comprising global temperature-sensitive transportation for the pharmaceutical and biotech industry.
The services of va-Q-tec ("Serviced Rental") enable customers to operate cold chains worldwide that are not only secure but also efficient in terms of cost and energy. For this purpose, va-Q-tec offers and maintains a fleet of rental containers ("va-Q-tainers") that are in demand particularly from pharmaceutical and biotech customers. Since 2015, the Group has also been offering a rental business for its high-performance thermal transportation boxes. Through optimally integrating high-performance insulation with vacuum insulation panels (VIPs) and the storage of thermal energy by means of phase change materials (PCMs), the packaging systems of va-Q-tec hold temperatures constant between 24 and 200 hours.
Other network stations that have been opened during the current year in Japan, India, Australia and Italy bolster the presence of va-Q-tec in the APAC region as well as Southern Europe and the availability of services in the markets situated there. Customers can now utilise a total of 25 network stations worldwide. The rental container fleet grew by more than 200 units in the first half of 2017, with a further 250 planned for the second half of the year. With more than 1,200 passively temperature controlled containers, va-Q-tec thereby already commands the largest fleet of this type today and the second largest of any type at all in the market. These measures form the basis for the further global growth of va-Q-tec.
During the first half of 2017 va-Q-tec has also added to its partner network of airlines, freight forwarding companies and other logistics partners. Extensive partnerships were arranged with additional airlines such as Emirates SkyCargo, TAP Cargo and Egyptair Cargo, for instance. Such partnerships further enhance the availability of va-Q-tec rental containers for pharmaceuticals customers, especially in Asia, Latin America and the Middle East.
Dr. Joachim Kuhn, CEO der va-Q-tec, comments on the service business for the global pharmaceuticals and biotech industries: "With our rental solutions in the box and container area, we see ourselves as offering a disruptive technology at a very attractive price. We are pleased that our intensive development work is increasingly paying off. "Serviced Rental" is of the greatest strategic importance for va-Q-tec. We see ourselves on a massive growth path in this context - an appraisal that also underscores the enthusiasm of both new and existing customers for our passive systems. Overall, we thereby aim to revolutionise cold chain logistics, starting with the pharmaceuticals cold chain. Finally, the regulatory influence to guarantee secure cold chains is growing, and not only in the pharmaceutical and biotech industry."
|Phone:||+49 (0)931 35 942 0|
|Fax:||+49 (0)931 35 942 10|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|